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Trp53 mutations are the most frequent genetic alterations in prostate cancer and are
associated with more aggressive disease and worse overall survival. The majority of Trp53
mutations in prostate cancer are missense mutations, resulting in amino acid substitutions with
profound effect. In addition to the loss of wild type function, missense mutations in Trp53
result in a gain-of-function (GOF) phenotype. This GOF phenotype confers biologic
advantages to the tumor cells, enabling them to metastasize and invade distant organs. In this
study, we generated mice carrying a conditional prostate-specific p53R245W mutant and Pten
deletion to access the role of this common p53 mutant in the pathogenesis and metastasis of
prostate cancer. We found that Trp53R245W/- Pten-/- mice have invasive prostate cancer with
complete penetrance and showed stable expression of the mutant p53. In addition, we found
metastasis in Trp53R245W/- Pten-/- mice (3/15), which was absent in Trp53-/- Pten-/- mice (0/14).
Analysis of metastasis also showed stable expression of the mutant p53. Taken together, these
results indicate that p53R245W mutation has GOF in Pten-deficient prostate cancer.
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Chapter 1: Introduction
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Prostate cancer (PCa) is the most common cancer among men in the Western world,
and is the second leading cause of cancer related death among men. More than 95% of all PCa
are adenocarcinoma. These tumors follow a sequential progression, from normal epithelium to
prostatic intraepithelial neoplasia (PIN), then to PCa. The development of metastatic PCa may
occur if the tumor gains additional growth advantages. Each step in this progression can be
thought of as a result of genetic alteration(s), with each gene playing different role(s). The
progression to metastasis deserves special attention due to its importance on morbidity and
mortality. Metastasis then is defined as the spread of cancer cell from its primary site to a
distant site via lymphatic or hematogenous route. This is in contrast to local invasion, where the
tumor cell only invades neighboring tissue via direct extension. In humans, the three main sites
of PCa metastasis are lower vertebra-proximal femur, lungs, and liver.
PCa displays significant intratumoral morphological heterogeneity, with areas of PIN,
various grades of PCa, and necrosis. Another feature of PCa is its genetic heterogeneity,
containing multiple independent foci of cancer that are often genetically distinct1. These
characteristics of PCa carry clinical significance. A tumor focus with high metastatic potential
might metastasize early and cause significant morbidity and mortality even after surgical
removal of the primary site whereas a nearby focus with low metastatic potential might be
locally invasive throughout its lifetime and would only require surgical removal and/or close
observation. A better understanding of the molecular/genetic mechanisms underlying these
differences is critical to improve the current management strategies for PCa.
Phosphatase and tensin homolog deleted on chromosome 10 (Pten), Androgen Receptor
(AR), and Trp53 are among the most frequently altered genes in prostate cancer and are
associated with more aggressive diseases and worse overall survival2; 3. Pten is a dual
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phosphatase that, through its lipid phosphatase activity, serves to oppose PI3K activity.
Inactivation of Pten leads to uncontrolled PI3K/AKT/mTOR signaling cascades, resulting in
increased cell growth, cell survival, and migration, and decreased apoptosis and cell cycle
arrest. AR is a nuclear hormone receptor that plays important roles in both normal prostate
development and PCa growth. The expression of AR varies in PCa1. A recent study shows that
Pten deletion can suppress AR transcription output, and that this suppression plays a role in the
development of castration resistant growth, regardless of the actual AR expression level4. p53
is a transcription factor that functions as a tetramer. It has low expression in normal tissue.
Upon cellular stress, p53 is upregulated and stimulates the expression of its myriad of target
genes. One such target is p21, which binds cyclin-CDK complexes and inhibits their activity,
arresting the cell cycle to allow time for proper cellular repair5. Cellular stress also upregulates
p14Arf, which decreases MDM2 activity. This will inhibit MDM2-mediated degradation of p53,
allowing the damaged cell to undergo apoptosis6.
Inactivation of Pten is identified in ~ 30% primary PCa, and as high as 60% in
metastasis7. Many studies have investigated the mechanism of Pten inactivation, and although
the rates vary depending on the grade and stage of the tumors and the assays that were used, all
seem to agree that genomic deletions account for the majority, with 15-20% deletion seen in
primary PCa and ~ 40% deletion seen in metastasis. Other mechanisms of Pten inactivation
make up the minority and include genomic rearrangement, DNA methylation, truncating
mutations, and a few missense mutations8. Another important feature of Pten is its
haploinsufficiency. This characteristic is supported by observations that monoallelic Pten loss
in mice is sufficient to induce PIN, a precursor to PCa, but these mice never progress to PCa. In
contrast, hypomorphic models, in which the mice contain only one copy of the Pten allele
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(Ptenhypo/-) and that protein expression from this allele is below that of wild type allele,
exhibited PCa with aggressiveness corresponding inversely to the Pten protein level9. Finally,
homozygous deletion of Pten results in early embryonic lethality10.
It is evident that Pten plays a role both in prostate tumorigenesis and in tumor
progression (Figure 1). Indeed, while monoallelic Pten loss is sufficient to induce PIN in mice
at 12-16 months of age11, biallelic Pten loss results in a much more rapid development of PIN,
usually within 9 weeks. This is then followed by a long latency period (4-6 months) before
development of PCa. Chen et al. (2005) showed that this latency period represents cellular
senescence, where the tumor cell undergoes permanent cell cycle arrest, and is mediated by the
presence of wild type p53. This senescence phenotype is ablated by deletion of p53, resulting in
a dose-dependent acceleration of carcinoma development in Pten null prostate. In this sense,
p53 also displays a characteristic of haploinsufficiency.

Figure 1. Overview of Pten and p53 roles in prostate cancer. Pten+/- results in PIN, but not
PCa. Pten-/- results in rapid (6-9 weeks) development of PIN and after a long latency (4-6
4

months), in PCa. p53 deletion, on the other hand, does not play a role in the initiation of PCa,
but has significant role in the progression of PCa. As shown in the diagram, it allows cells in
PIN stage to bypass senescence and progress to advanced PCa, the aggressiveness of which
depends on the dosage of p53 (This figure was obtained from Shen, M.M., and Abate-Shen, C.
(2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes &
development 24, 1967-200012. It was modified and printed under Creative Commons
Attribution-NonCommercial 4.0 International Public License.)
Although p53 has a limited role in the initiation of PCa, it plays a significant role in the
progression of PCa (Figure 1). Homozygous deletion of Trp53 in mice, without other genetic
alteration, does not lead to PCa. Chen et al. showed that prostates from these mice were
indistinguishable from those of wild type mice, even after 18 months follow up13. p53 does,
however, accelerate the progression of PCa initiated by other genetic events, including Pten
inactivation. Homozygous double deletion of Pten and Trp53 in mouse prostate epithelial cells
leads to invasive PCa with key features of human castration-resistant prostate cancer (CRPC)14.
However, despite the aggressive nature of PCa in mice from homozygous double deletion
models, there has been no evidence of metastasis, even after extended follow up13; 15; 16.
p53 missense mutations, particularly in the hotspot region between codons 125 and 300,
exhibit gain of function (GOF) phenotypes, specifically metastasis to many tissues. Besides the
classic Li-Fraumeni Syndrome models harboring germline missense mutations in p5317; 18,
there have been more recent models harboring somatic missense mutations in p53 that resulted
in high frequency of metastasis19; 20. The GOF mechanism that has been described in these
recent models involves the interaction of mutant p53 with other transcription factors, affecting
expressions of target genes that favor tumor growth21. There are two prerequisites for this
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mechanism to be effective: 1) stabilization of the mutant p53 and 2) availability/accessibility of
the interacting transcription factors. When these prerequisites are met, the downstream effects
can be profound. For example, the R248W mutant can interact with either p63 or p73 tumor
suppressor, neither of which binds to wild type p53. These novel interactions inhibit the
expression of target genes that are important for tumor suppression downstream. The R248W
mutant can also bind Ets2 and Sp1, forming new complexes that stimulate the aberrant
expression of other target genes that are important for GOF properties. By interacting with
multiple transcription factors and affecting changes in the expression of multiple target genes,
the R248W mutant can amplify its GOF activities severalfold21.
Since the above mechanisms require stable mutant p53 and availability/accessibility of
interacting transcription factors, any condition that changes this dynamic can prevent mutant
p53 from manifesting its GOF properties. On the one hand, mutant p53, similar to its wild type
counterpart, is inherently unstable. Tumor specific signals, including DNA damage, reactive
oxygen species, activation of oncogenes, and inactivation of another tumor suppressor, are
required for the stabilization of mutant p5322. On the other hand, cellular and tumor
microenvironment signals, such as hypoxia, changes in pH, inflammation, and interactions with
stromal cells, can affect the availability/accessibility of interacting transcription factors21. In
addition, any of these conditions can change with disease, cell type, and even within the same
tumor owing to heterogeneous mutant p53 stabilization23.
The site within the hotspot region at which missense mutation occurs also plays a
potentially important role in the manifestation of GOF properties. Missense mutation in the
hotspot region can result in either a structural p53 mutant, where the DNA-binding domain
structure is altered, or a contact mutant, where an arginine residue that normally interacts with
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target gene DNA is substituted with another amino acid24. Figure 2 shows the structure of p53
protein and some of the most common structural and contact mutants in PCa. Zhang et al
(2018) showed that both the p53R172H structural mutant and p53R245W contact mutant drive
metastasis in breast cancer, but that the contact mutant exhibited a significantly higher
incidence of metastasis than the structural mutant counterpart20. Although the mechanism for
this difference was not specifically defined, there are a couple of plausible reasons for this
difference. First, the two mutants might bind different interacting transcription factors hence
affect expression of different target genes. Secondly, the two mutants might bind the same
interactors and affect the expression of the same target genes, but that the contact mutant binds
to its target genes with a higher affinity hence affect the expression of those target genes to a
greater degree than the structural mutant21; 24.

Figure 2. Human p53 protein domain structure and common sites of missense mutations
in PCa. Human p53 is composed of 393 amino acid residues. The majority of mutations in p53
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occurs between codons 125 and 300. Mutations at the four amino acids highlighted here are the
most common in PCa. NLS = nuclear localization sequence; NES = nuclear export sequence.
(This Figure was obtained from Tanaka, T., Watanabe, M., and Yamashita, K. (2018). Potential
therapeutic targets of TP53 gene in the context of its classically canonical functions and its
latest non-canonical functions in human cancer. Oncotarget 9, 16234-1624725. It was modified
and printed under Creative Commons Attribution License 3.0 (CC BY 3.0).)
In regards to PCa, the latest data from cbioportal.org includes a total of 4850 PCa
samples, of which 930 (20%) have alterations in Trp53 (Figure 3a). Although the alteration
frequency is different among the studies, possibly due to sample size, differences in grade/stage
of the profiled samples, and/or sequencing methods that were used, all seem to agree that
mutation accounts for the majority of p53 alterations in PCa. Specifically, 581 out of these 930
alterations are missense mutations, and 307 of these 930 alterations are truncating mutations
(Figure 3). Most of the mutations are congregated in the hotspot region, with mutations at the
248 and the 273 codons being the two most common.
To better understand the role of p53 missense mutation in the pathogenesis and
metastasis of PCa, we generated mice carrying conditional prostate-specific p53R245W mutant
and Pten deletion. Missense mutation at R245 results in a contact mutant that substitutes
arginine with another amino acid, and in the case of R245W, with tryptophan. Considering the
GOF roles of R248 mutation (R245 in mice) in other tissues and the relative prevalence of
R248 mutation in prostate cancer metastasis, we predict that our Trp53R245W/- Pten-/- model will
yield a metastatic phenotype.
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Figure 3. Prevalence of Trp53 mutations in PCa.
a) Alteration frequency of Trp53 in PCa across 18 different studies obtained from
cbioportal.org. Notice the majority are mutations (green bars).
b) Mutations mapped to the p53 protein structure, obtained from cbioportal.org.
c) Zoom-in view of the five most common amino acids that are mutated in PCa. The height of
the bars represents the number of PCa samples with the particular mutation, per 4850 total
PCa samples profiled. The blue bars represent the number of all positive PCa samples with
the particular mutation (R175H = 24/4850, G245S = 21/4850, R248Q = 47/4850, R248W =
11/4850, R273C = 43/4850, R273L = 10/4850, R273H = 14/4850, R282W = 21/4850). The
orange bars represent the number of known metastatic PCa samples with the particular
10

mutation (R175H = 11/4850, G245S = 4/4850, R248Q = 18/4850, R248W = 3/4850,
R273C = 16/4850, R273L = 5/4850, R273H = 11/4850, R282W = 7/4850).
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Chapter 2: Generation of prostate specific Trp53R245W/- Pten-/- and Trp53-/- Pten-/- mice
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To determine if R245W mutant promotes formation of Pten deficient PCa, we generated
compound mice using Probasin Cre4 (Pb-Cre4)26. This model allows for prostate specific
recombination and expression of the R245W mutant allele, prostate specific deletion of Pten,
and prostate specific expression of Rosa26-LSL-tdTomato (TdT), a conditional allele that
expresses tomato red fluorescent protein in response to Cre27.
The p53R245W mutant mice were generated using the Trp53wm-R245W allele construct,
which was produced by inserting partial wild-type p53 cDNA encoding exons 7-11 (with the
poly A signal), flanked by loxP sites, into intron 6 of the mutant p53R245W allele (Fig 4a). In
the absence of Cre recombinase, the Trp53wm-R245W allele expresses p53 protein that maintains
wild type function20. In prostate epithelial cells, Probasin driven Cre recombinase excises the
inserted cDNA to generate the Trp53R245W mutant allele that expresses the p53R245W mutant
protein.
To generate Trp53-/- Pten-/- mice, we made multiple crosses of male PB-Cre4 mice
(C57BL/6 x DBA2 background) with female mice carrying either the Trp53loxP allele (mixed
C57BL/6/129 S background) or the PtenloxP allele (mixed C57BL/6 FVB/N background). We
then bred the subsequent Trp53-/- Pten-/- progeny with mice carrying the Trp53wmR245W allele
(C57BL/6/129 S background) to get the desired Trp53R245W/- Pten-/- genotype. We also tried to
incorporate TdT in our crossing, but this was not used in our inclusion criteria. In total, we
were able to generate 14 mice for our Trp53-/- Pten-/- cohort, 15 mice for our Trp53R245W/- Pten-/cohort, and 10 PbCre- mice for our wild type control. The mice were monitored routinely
according to protocols set by M.D. Anderson Cancer Center Institutional Animal Care and Use
Committee. We followed these mice over a period of 10 months for survival analysis. Prior to
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the current project, our lab also generated 12 Pten-/- mice, which will be included in the survival
analysis for comparison purposes.
While PB-Cre4 mice was documented as showing robust, tissue-specific, and post-natal
expression of Cre in the prostate epithelium26, there have been reports of scattered Cre
expression in non-prostatic tissues, namely the seminal vesicles, testis, and ovary26; 28.
Although the limited expression of Cre in seminal vesicles and testis was not shown to be
significant, the expression in ovary was shown to result in non-specific allele recombination in
the developing embryo. This non-specific recombination only occurs if the transmission of Cre
is through maternal carrier28. For this reason, we limited the transmission of Cre through
paternal carrier, sacrificing any female mice that showed positive PB-Cre4 allele in our
genotyping. To test the specificity of our PB-Cre4 system, we demonstrated that Cre-mediated
recombination of allele was restricted to the prostate (see Figures 4 and 5).
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Figure 4. Cre-mediated Trp53wm-R245W allele recombination is specific to the prostate.
a) Schematic representation of Trp53wm-R245W allele. Red triangle loxP site; light blue
rectangle Frt site left after removing the selection marker; A, Trp53 polyadenylation signaling
sequence; * 733 C→T and 735 C→G mutations were introduced in exon 7 for the Trp53wmR245W

allele. (This figure was obtained from Zhang, Y., Xiong, S., Liu, B., Pant, V., Celii, F.,

Chau, G., Elizondo-Fraire, A.C., Yang, P., You, M.J., El-Naggar, A.K., et al. (2018). Somatic
Trp53 mutations differentially drive breast cancer and evolution of metastases. Nature
communications 9, 395320. It was printed with permission from Nature Publishing Group under
license number 4590980970297.)
b) PCR results for the Trp53wm-R245W allele prior to recombination (left) and after
recombination (right). The 500 bp mark represents the Trp53wm-R245W allele prior to
recombination, as detected by using primers surrounding the 5’ loxp site. The 427 bp mark
15

represents the Trp53R245W allele after recombination, as detected by using primers surrounding
the mutated site in exon 7. Notice the presence of the R245W recombinant allele in the
prostate, but absence of the allele in other tissues.

Figure 5. Cre-mediated Pten deletion is specific to the prostate.
a) Schematic of Pten genomic structure and recombinant alleles. The transcript from the
Pten null allele eliminates exon 5, resulting in a translational frameshift. B, BgIII; S, SacI; E,
EcoRI; X, XhoI; A neomycin-resistance cassette was flanked by Flp recombination target
(FRT) sites (white bars), and a Cre recognition LoxP site immediately upstream of the 5’ FRT
16

was placed 5’ of exon 5 (arrow). A second LoxP site is placed downstream of exon 5 (arrow).
(This figure was obtained from You, M.J. (2010). Mouse Models of Lymphoma and Lymphoid
Leukemia In Neoplastic Hematopathology, D. Jones, ed. (Humana Press), p 59329. It was
printed with permission from Humana Press under license number 4613860057704.)
b) PCR results for Ptenloxp allele and Ptennull allele. Notice the presence of the Ptennull
allele (210 bp) in the prostate, and absence in other tissues. The 974 bp mark represents the
Ptenloxp allele prior to Cre-mediated deletion.
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Chapter 3: Prostate specific Trp53R245W/- Pten-/- alterations elicit adenocarcinoma with
complete penetrance
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Considering the aggressiveness of tumors with R245W mutants in other tissues20, we
suspected that PCa in our Trp53R245W/- Pten-/- mice to also exhibit aggressive characteristics.
Indeed, of the mice in our Trp53R245W/- Pten-/- cohort, all (15/15) developed adenocarcinoma of
the prostate (see Table 1). Fluorescence imaging of TdT+ mice showed positive signs of tumor
starting at ~ 20-21 weeks of age (Figure 6). By 24 weeks of age, most mice had visibly
enlarged abdomen, and by 28-30 weeks of age, almost all mice had enlarged abdomen to >
2cm, at which time they were marked for euthanasia. Survival is defined at the time the mice
were marked for euthanasia and/or at the time of actual death. Kaplan-Meier survival curve of
Trp53R245W/- Pten-/- cohort shows no statistically significant difference compared to Trp53-/Pten-/- cohort (Figure 7). It is worth to mention that tumor onset and progression, as accessed by
fluorescence imaging and daily inspection, of the Trp53R245W/- Pten-/- mice cohort is very similar
to that of the Trp53-/- Pten-/- mice cohort (data not shown). Finally, the average weight of the
primary tumor in Trpp53R245W/- Pten-/- mice is also similar to that of Trp53-/- Pten-/- mice (Figure
8).
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Table 1. Prostate histologic diagnosis and IHC results of Trp53R245W/- Pten-/- and Trp53-/Pten-/- mice. IHC results: for Pten, negative results indicate that > 80% of cells are negative; for
p19Arf, positive results indicate that > 50% of cells are positive; for p53, positive results
indicate that > 35-40% of cells are positive; for p21, negative results indicate that > 80% of
cells are negative; for AR, negative results indicate that > 80% of cells are negative. IHC
results for p19Arf and AR were also quantified using imageJ (see Materials and Methods
section).
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Figure 6. Fluorescence imaging of TdT+ and TdT- PCa.
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Figure 7. Survival analysis curve of PCa.
Kaplan-Meier plot shows no statistical difference in survival between Trp53R245W/- Pten-/- cohort
and Trp53-/- Pten-/- cohort; p value = 0.3007

Figure 8. Gross characteristics of PCa in Trp53R245W/- Pten-/- and Trp53-/- Pten-/- mice.
Gross images of PCa in a) Trp53R245W/- Pten-/- mice at 28 weeks and b) Trp53-/- Pten-/- mice at
28.7 weeks. c) Average weight of PCa in Trp53R245W/- Pten-/- mice (n=7) vs Trp53-/- Pten-/- mice
(n=5). P value = 0.3830.
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On a microscopic level, the PCa in Trp53R245W/- Pten-/- mice show poorly differentiated
adenocarcinoma with many other aggressive features. As seen in Figure 9, these PCa cells are
largely abnormal, with nuclear atypia, prominent nucleoli, and visible mitoses. Necrosis and
angiogenesis, two features marking aggressive growth of tumors, can be seen adjacent to areas
of carcinoma. PIN, a precursor to carcinoma, can also be seen within one low power field
(10X). This juxtaposition of high-grade adenocarcinoma, necrosis, and angiogenesis with PIN
highlights the morphological heterogeneity of PCa. Lastly, IHC stain for Ki67 show that PCa
from these mice are highly proliferative, with all PCa samples showing > 20% Ki67 positive
cells. These aggressive features are also seen in PCa from Trp53-/- Pten-/- mice (data not
shown).
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Figure 9: Histology of PCa in Trp53R245W/- Pten-/- mice.
H&E stain of PCa in Trp53R245W/- Pten-/- mice show morphological heterogeneity containing
24

areas of PCa, angiogenesis a), necrosis b), and PIN b).
c) IHC stain shows > 50% of Ki67 positive cells.
IHC stain for p53 shows that Trp53R245W/- Pten-/- prostates express abundantly stable
mutant p53, but only in areas with carcinoma and not in normal areas or PIN (Figure 10a). To
determine the mechanism of mutant p53 stabilization in Pten deficient PCa, we first performed
IHC stain of Pten to confirm that it is deleted (Figure 10b). Next we looked at the level of
p19Arf, which has been shown to stabilize mutant p5322; 23, and also been shown to accumulate
in response to Pten loss13; 30. We found that the level of p19Arf is indeed increased in Pten
deficient PCa relative to that of age matched PbCre- control (Figure 10c). Finally, to determine
that the positive stain of p53 is of mutant and not of wild type protein, we showed that the
expression of p21 is not upregulated relative to PbCre- control (Fig 10d).

25

26

PbCrep53R245W/- Pten-/-

Figure 10. Accumulation of p19Arf leads to stabilization of mutant p53 in Pten deficient
PCa.
IHC stain for p53 shows that a) Trp53R245W/- Pten-/- prostate expresses abundantly stable mutant
p53, but only in areas with carcinoma and not PIN.
b) IHC stain for Pten in Trp53R245W/- Pten-/- PCa (top) and in PbCre- control (bottom).
c) IHC stain for p19Arf in Trp53R245W/- Pten-/- PCa (top) and in PbCre- control (bottom).
d) IHC stain for p21 in positive control (top), in Trp53R245W/- Pten-/- PCa (middle), and in
PbCre- control (bottom).
e) number of p19Arf positive cells per one low power field (100x) in Trp53R245W/- Pten-/- PCa and
PbCre- control; p value = 0.0059.
Considering the documented literature linking the development of CRPC and the
suppression of AR transcription output in Pten deficient PCa4, we tested for the IHC level of
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AR in PCa from both our Trp53R245W/- Pten-/- and our Trp53-/- Pten-/- cohorts. We found that the
expression of AR is downregulated in Pten deficient PCa relative to PbCre- control (Fig 11),

PbCre-

p53R245W/- Pten-/-

p53-/- Pten-/-

supporting the study that Pten deletion suppresses AR transcription output.

Figure 11. AR is downregulated in Pten deficient PCa.
a) IHC stain of Pten in Trp53-/- Pten-/- PCa (top), Trp53R245W/- Pten-/- PCa (middle), and in
PbCre- control (bottom).
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b) IHC stain of AR in Trp53-/- Pten-/- PCa (top), Trp53R245W/- Pten-/- PCa (middle), and in
PbCre- control (bottom).
c) Number of AR positive cells per one low power field (100x) in Trp53-/- Pten-/- PCa,
Trp53R245W/- Pten-/- PCa, and PbCre- control.
Although significant differences between the Trp53R245W/- Pten-/- cohort and the Trp53-/Pten-/- cohort do not exist based on phenotypic evaluation of primary PCa, a few conclusions
can reasonably be drawn from our results. First, Trp53R245W/-, similar to Trp53-/-, promotes the
formation of Pten deficient PCa. These PCa show complete penetrance and exhibit many signs
of aggressive phenotype. The morphology of these PCa mimics that of human: adenocarcinoma
and intratumoral morphological heterogeneity. Secondly, the p53R245W mutant is stable in the
majority of our Trp53R245W/- Pten-/- cohort (13/15 or 87%). Finally, although we have not found
significant differences in tumor onset between the two cohorts based on macroscopic
evaluation, by no means can we assume there were no early histological differences in the
initiation of PCa between these two cohorts.
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Chapter 4: Metastatic potential of Trp53R245W/- Pten-/- mice
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To determine the metastatic potential of R245W mutant mice, we performed gross
dissections of all visible lymph nodes. Out of 15 mice from our Trp53R245W/- Pten-/- cohort, we
were able to isolate five mesenteric lymph nodes, and upon H&E stain, three were shown to be
positive for adenocarcinoma and two were normal lymphoid tissues (Table 2). We then
performed IHC stain for cytokeratin AE1/AE3 on the positive lymph nodes to confirm that the
adenocarcinoma is of prostate origin (Figure 12g). By the same manner, out of 14 mice from
our Trp53-/- Pten-/- cohort, we were able to isolate four mesenteric lymph nodes, all of which
were shown to be normal lymphoid tissues upon H&E stain. To evaluate for mutant p53
stability in metastasis, we performed IHC stain for p53 on the positive lymph nodes and found
that they are indeed stable (Figure 12e).

Table 2. Metastasis of PCa in Trp53R245W/- Pten-/- and Trp53-/- Pten-/- mice cohorts.
1

Ten micron-interval sections of liver and bilateral lungs were examined with H&E.

2

Ten serial sections of lower vertebra-proximal femur were analyzed with H&E.
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Primary PCa

Metastasis

Figure 12. Metastasis of Trp53R245W/- Pten-/- PCa shows stable expression of the p53R245W
mutant protein.
a) Gross image showing metastasis to mesenteric lymph node.
H&E stain of b) primary PCa and d) metastasis. Notice that in d), metastatic carcinoma had
completely replaced the normal lymphoid tissue.
p53 stain of c) primary PCa and e) metastasis.
f) and g) IHC stains for cytokeratin AE1/AE3 in primary tumor and metastasis are positive,
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confirming metastasis is of prostate origin.
Besides lymph nodes in the Trp53R245W/- Pten-/- cohort, there were no overt metastasis in
other tissues/organs identified in either the Trp53R245W/- Pten-/- or the Trp53-/- Pten-/- cohort.
Considering the three main sites of prostate cancer metastasis in humans are lower vertebraproximal femur, lungs, and liver, we also looked at these organs for possible micrometastasis.
Specifically, ten micron-interval sections of liver and bilateral lungs were analyzed with H&E,
the results of which were negative. Ten serial sections of lower vertebra-proximal femur were
also analyzed with H&E, the results of which were also negative (see Table 2).
To compare the metastatic potential of PCa cells in Trp53R245W/- Pten-/- mice relative to
that of Trp53-/- Pten-/- mice, we performed invasion assays of PCa cell lines from the two
groups (Figure 13). As can be seen, invasion is higher in Trp53R245W/- Pten-/- PCa cell lines vs
that of Trp53-/- Pten-/- PCa cell lines, supporting the higher metastatic potential of Trp53R245W/Pten-/- PCa and hence the GOF phenotype of the R245W mutant.
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Figure 13. Invasion assays of Trp53-/- Pten-/- and Trp53R245W/- Pten-/- PCa cells.
a) Images of the invading cells.
b) Quantification of the invading cells from the Trp53-/- Pten-/- (n = 3) and the Trp53R245W/Pten-/- (n = 4) cohorts. P value = 0.0275.
In this section, we have shown that mice from Trp53R245W/- Pten-/- cohort exhibited a
metastatic phenotype, which was absent in the Trp53-/- Pten-/- cohort. Specifically, three out of

34

fifteen Trp53R245W/- Pten-/- mice developed metastasis to lymph nodes remotely located from
primary tumors. All of these lymph nodes showed stable expression of the mutant p53.
Although the penetrance is low (20%), the lesions that we did identify are macroscopic (see
Figure 12a), and the metastatic lesions completely replaced the normal lymphoid tissue (see
Figure 12d). Furthermore, due to our limited number of sections, we cannot exclude the
possibility of micrometastasis in bones, lungs, and liver. Regardless, a few conclusions can be
drawn from our data. First, Trp53R245W/- Pten-/- mice exhibited grossly identifiable metastasis
(3/15), whereas Trp53-/- Pten-/- mice showed no metastasis (0/14). Secondly, the majority of
Trp53R245W/- Pten-/- mice show stable expression of the mutant p53, both in the primary tumor
(13/15) and in the metastasis (3/3). Lastly, PCa cell lines from Trp53R245W/- Pten-/- mice show
increased invasion in culture compared to those from Trp53-/- Pten-/- mice. These three
conclusions point to the p53R245W mutant as the likely driver for prostate cancer metastasis.
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Chapter 5: Discussion and future directions
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In this study, we have shown that Trp53R245W/- promotes the formation of Pten deficient
PCa. Primary PCa in Trp53R245W/- Pten-/- mice, similar to that of Trp53-/- Pten-/- mice, are poorly
differentiated adenocarcinoma with complete penetrance and exhibit many other histological
features of aggressive growth. Furthermore, we have also shown that the R245W mutant
exhibit a GOF phenotype in Pten deficient PCa in the formation of metastasis. The fact that
R245W mutant is stable in areas of carcinoma and in metastasis but not in normal area or PIN
suggests that within the heterogeneous prostate, R245W mutant is only stable in certain groups
of cells and promote cancer formation and metastasis from those groups of cells. When R245W
mutant is not stable, cancer metastasis appears to be arrested in those groups of cells.
Regarding the mechanism of mutant p53 stabilization, our IHC results indicate that
homozygous deletion of Pten might play a role in that it leads to increased accumulation of
p19Arf, which has been shown to inhibit Mdm2-mediated degradation of p5322; 23. The fact that
there is strong positive staining of p53 but not of p21 suggests that the positive staining
represents the R245W mutant cell and not of normal adjacent cell. Considering PCa from the
majority of our Trp53R245W/- Pten-/- mice have stabilized mutant p53 (13/15), we would expect
to find more metastasis. The fact that we only found three metastasis suggests that 1) the ten
cross sections were not enough to thoroughly look at the aforementioned organs for
micrometastasis; or 2) the primary PCa from our Trp53R245W/- Pten-/- mice reached the size limit
for euthanasia prior to forming identifiable metastasis.
Of the three PCa cell lines that we were able to secure from our Trp53R245W/- Pten-/mice, all showed increased invasion relative to those from Trp53-/- Pten-/- mice. We would also
like to perform migration assays of PCa cell lines from the two cohorts to further characterize
the metastatic potential. In terms of downstream mechanisms of R245W driven metastasis, we
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will perform RPPA analysis and RNA sequencing of the metastatic Trp53R245W/- Pten-/- PCa and
of the nonmetastatic Trp53-/- Pten-/- PCa. We will then perform pathway analysis and validate
our results with functional studies.
A notable difference in prostate anatomy in mice versus that in human is that in mice,
the prostate is a multi-lobular structure consisting of the ventral, lateral, dorsal, and anterior
lobes. In human, the prostate is arranged in a zonal architecture consisting of the central,
periurethral, and peripheral zones. The peripheral zone occupies the most volume and is the site
of most common occurrence of prostate cancer. Analysis of gene expression profiling supports
the notion that the dorsolateral lobe in mouse prostate is most analogous to the peripheral zone
in human prostate31. The pattern of Cre expression, being highest in the lateral lobe, followed
by the ventral, and then the dorsal and anterior lobes, in PB-Cre4 system accurately mimics this
preferential site for carcinoma formation in human26.
While our current model supports the GOF property of R245W mutant in PCa in the
formation of metastasis, it might not completely recapitulate the in vivo process of PCa
formation in human. PCa formation in human is a slow and insidious process, requiring
cumulative effects of genetic and environmental factors. Although the formation of PCa
generally follows PIN, and the formation of metastatic PCa may occur once PCa is formed,
these progressions are very subtle. For this reason, a heterozygous model (Trp53R245W/+), one
that is predicted to have a more gradual onset of cancer formation, progression, and metastasis
than the Trp53R245W/- model, would more closely recapitulate prostate cancer pathogenesis in
human.
Despite some of the limitations of our model, if our study can define the role of R245W
mutant in driving metastasis in PCa, this would have a significant impact in the current clinical
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management of the disease. While surgical prostatectomy is usually performed once a
diagnosis of high-grade prostate cancer is confirmed, androgen deprivation therapy (ADT) will
also be initiated for those that present with metastasis. However, after a short period of
responsiveness, patients will develop resistance to ADT, at which stage, treatment is very
limited. Considering the prevalence of R248 and other missense mutations in prostate cancer
metastasis, understanding the mechanism that drives metastasis in these mutations will
potentially give clinicians novel therapeutic targets to either prevent metastasis or treat the
existing metastatic disease. Specifically, for cases with p53 mutation and Pten deletion, one
such strategy would be to inhibit p14Arf in order to prevent mutant p53 stabilization and
accumulation, thereby suppressing its GOF activities.
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Chapter 6: Materials and Methods
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Generation of Mice
We obtained PB-Cre4 mice (C57BL/6 x DBA2 background) from Jackson lab26; mice carrying
p53loxP allele and p53wmR245W allele (both mixed C57BL/6/129 S background) from our
collaborator Dr. Gigi Lozano19; 20 ; and mice carrying PTENloxP allele (mixed C57BL/6 FVB/N
background) is maintained in our lab32. Mice were crossed as described in Chapter 2. They
were monitored routinely and sacrificed in compliance with US Public Health Service Policy
on Humane Care and Use of Laboratory Animals. All study protocols were approved by M.D.
Anderson Cancer Center Institutional Animal Care and Use Committee.

DNA preparation and PCR analysis of Tp53 alleles
DNA was isolated from various mouse tissues by overnight lysis at 55°C in a buffer containing
proteinase K, followed by extraction and isopropanol precipitation. For each PCR reaction, 50100ng of genomic DNA was used. PCR program was set at: Initialization 95°c 5 minutes;
Denaturation 94°c 1 minute; Annealing 60°c 45 seconds; Extension 72°c 1 minute; Final
elongation 72°c 6 minutes; 30 cycles.
The primers used for Trp53wmR245W allele were forward: 5′-ACCTTATGAGCCACCCGA-3′;
reverse: 5′-GGAAGACACAGGATCCAGGT-3′.
Primers for Cre-mediated recombinant Trp53R245W allele were forward: 5’ATCCAGGCGGGAAATAGAG-3’; reverse: 3’-AGCGTTGGGCATGTGGTA-5’
Primers for Trp53flox allele were forward: 5’-AAGGGGTATGAGGGACAAGG-3’; reverse: 3’GAAGACAGAAAAGGGGAGGG-5’
Primers for Cre-mediated Trp53 floxed out allele were forward: 5’-CAC AAA AAC AGG
TTA AAC CCA G-3’; reverse: 5’- GAA GAC AGA AAA GGG GAG GG -3’
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Primers for Ptenflox allele were forward: 5’- CTTCGGAGCATGTCTGGCAATGC -3’; reverse:
3’- AAGGAAGAGGGTGGGGATAC-5’
Primers for PbCre were forward: 5’-TCTGCACCTTGTCAGTGAGG-3’, reverse: 5’ATGTTTAGCTGGCCCAAATG-3’

Histology and Immunohistochemical (IHC)
Tissues were fixed in 10% v/v formalin and embedded in paraffin. Sections were stained with
haematoxylin and eosin (H&E) by the MDACC Research Histology Core Laboratory, The
University of Texas MD Anderson Cancer Center, Houston, TX.
Tissues were also IHC stained by MDACC Science Park Research Histology, Pathology &
Imaging Core, Smithville, TX; using these antibodies:
p53 (CM5), Novacastra, #NCL-L-p53-CM5p, 1:250 at room temperature for 1.5 hours; Buffalo
Grove, IL.
Pten, Cell Signaling, #9559, 1:100 at 4o overnight; Danvers, MA.
p19Arf, Abcam, #ab80, 1:50 at 4o overnight; Cambridge, UK
p21, Santa Cruz, #sc-6246, 1:50 at 4o overnight; Dallas, TX
AR, Abcam, #ab74272, 1:200 at room temperature for 1 hour; Cambridge, UK
Ki67, Bethyl Labs, #IHC-00375-1, 1:250 at room temperature for 2 hours; Montgomery, TX
IHC results for p19Arf and AR were quantified using imageJ33; 34, and were graphed using
GraphPad Prism 8.

Primary cell culture
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Tumor was dissected and placed into a 10 cm petri dish with 5-10 mL of DMEM culture medium.
Tumor tissues were minced into small fragments (1-3mm3) using razor blades then followed by
trypsin treatment to obtain dissociated single cells from the tumor fragments. The cell solution
was mixed with 10 ml pipette, then filtered through a 70-100 µm sterile mesh to remove any
large and undigested tumor fragment. The filtered solution was then pelleted by centrifugation at
1200 rpm for 10 min. The cell pellet was then re-suspended with DMEM culture medium
containing 10% fetal bovine serum with 5% CO2 and kept incubated at 37 °C.

Invasion Assay
For in vitro Transwell invasion assay, the upper chamber (BD Bioscience) was pre-coated with
0.1ml of Corning matrigel, which was diluted 1:10 with serum free DMEM. Cells were cultured
in 10 cm dishes with 70%-80% confluence prior to sub-culturing into the invasion chamber. A
suspension of 1*105 cells was added into the upper chamber of each well, and 0.5 ml of DMEM
culture medium containing 10% fetal bovine serum was added to the lower portion of each well.
After 10hrs incubation, a cotton swab moistened with DMEM medium was inserted into the top
of the matrigel coated chambers to remove the non-invading cells. The chambers were then
placed into the methanol at room temperature for 10 min to allow for cell fixation, followed by
10 min staining with 0.2% crystal violet. The chambers were washed with PBS to remove the
crystal violet. The invading cells were evaluated under a microscope (Olympus) and images were
captured with the built-in camera. The invaded cells were counted using Image J and results were
analyzed and graphed using GraphPad Prism 8.
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